CD4 and cancer: Indeed, we found that rSmeg-hMIF-hIL-7 elicited an enhanced CTL response against CD4+ and CD8+ T cells cocultured with infected dendritic cells compared with rSmeg expressing h-MIF alone or h-IL-7 alone (figure 1), suggesting an adjuvant effect of IL-7 in cancer immunotherapy.